# US 2012/0252875 A1 · Methods and compositions for treating diseases, disorders or injury of the cns

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252875 A1
- Document ID: US20120252875A1
- Status: Published application
- Kind: A1
- Application number: 13/514,880
- Filed: 2010-12-09
- Published: 2012-10-04
- Earliest claimed: 2009-12-09
- Assignees: Quark Pharmaceuticals, Inc.
- Inventors: Elena Feinstein; Igor Spivak; Evgenia Alpert; Ron Lahav
- Web page: https://patentgrep.com/patent/US20120252875A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 9/0046: {Ear}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 49/00: Preparations for testing in vivo
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to non-invasive methods for treating diseases, disorders and injury to the central nervous system (CNS), and in particular to otic compositions and to methods of use thereof.

## Claims

### Claim 1

A method for inhibiting loss or injury of a retinal ganglion cell in a subject, comprising applying to the ear of the subject an otic composition comprising at least one double stranded RNA compound which down regulates expression of a target gene associated with loss of the retinal ganglion cell, in an amount effective to inhibit loss or injury of the retinal ganglion cell in the subject.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject is suffering from an ocular disease, an ocular disorder or an ocular injury or at risk of developing an ocular disease, an ocular disorder, or an ocular injury.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said ocular disease, disorder, or injury comprises neurodegeneration, increased intraocular pressure or optic nerve injury.

### Claim at position 4

4-5. (canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein said disease, disorder, or injury is selected from a group consisting of glaucoma, diabetic retinopathy (DR), diabetic macular edema (DME), age related macular degeneration (AMD), Leber's hereditary optic neuropathy (LHON), Leber optic atrophy, optic neuritis, retinal artery occlusion, central retinal vein occlusion, brunch retinal vein occlusion, ischemic optic neuropathy, optic nerve injury, retinopathy of prematurity (ROP) or retinitis pigmentosa (RP), retinal ganglion degeneration, macular degeneration, hereditary optic neuropathy, metabolic optic neuropathy, optic neuropathy due to a toxic agent or neuropathy caused by adverse drug reactions or vitamin deficiency.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the disease is glaucoma.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the disease is ischemic optic neuropathy.

### Claim at position 8

9-15. (canceled)

### Claim 16

A method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of an ocular disease associated with death of a retinal ganglion cell in a subject, comprising applying to the ear of the subject an otic composition comprising at least one double stranded RNA compound which down regulates expression of a target gene associated with the ocular disease, in an amount effective to provide ocular neuroprotection or prevent or treat the disease or alleviate the effects of the disease in the subject.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The method according to claim 1, wherein the retinal ganglion cell loss or injury results from optic nerve injury or disease, elevated intraocular pressure (IOP) or from an ischemic event in the subject.

### Claim at position 12

19-26. (canceled)

### Claim 27 (depends on 16)

The method of claim 16, wherein the ocular disease comprises visual field loss.

### Claim 28

An otic composition for treatment of an ocular disease associated with damage to or loss of a retinal ganglion cell in a subject or with pathological abnormalities or changes in the tissues of the visual system in a subject or with a disease, a disorder or an injury of the CNS, comprising: (a) a therapeutically effective amount of at least one double stranded RNA compound which down regulates expression of a target gene associated with the ocular disease, and (b) a pharmaceutically acceptable excipient or carrier or mixture thereof.

### Claim at position 15

29-31. (canceled)

### Claim 32 (depends on 28)

The composition according to claim 28, wherein the ocular disease is selected from a group comprising glaucoma, diabetic retinopathy (DR), diabetic macular edema (ONE), age related macular degeneration (AMD), Leber's hereditary optic neuropathy (LHON) or Leber optic atrophy, optic neuritis, retinal artery occlusion, central retinal vein occlusion, brunch retinal vein occlusion, ischemic optic neuropathy, optic nerve injury, retinopathy of prematurity (ROP) or retinitis pigmentosa (RP), retinal ganglion degeneration, macular degeneration, hereditary optic neuropathy, metabolic optic neuropathy, neuropathy due to a toxic agent or that caused by adverse drug reactions or vitamin deficiency.

### Claim at position 17

33-37. (canceled)

### Claim 38

A kit comprising: (a) a therapeutic oligonucleotide that targets a gene associated with an ocular disease or a disease, disorder or injury of the CNS; and (b) instructions for using the oligonucleotide to treat the disease, disorder or injury.

### Claim at position 19

39-40. (canceled)

### Claim 41 (depends on 28)

The method according to claim 28, wherein the composition is formulated for topical administration to the ear canal.

### Claim 42

(canceled)

### Claim 43

A method of attenuating expression of a target mRNA in a subject suffering from a disease, a disorder or an injury of the CNS associated with expression of the target mRNA, which comprises applying to the ear of the subject an otic composition comprising at least one oligonucleotide compound which down regulates expression of the target mRNA and a pharmaceutically acceptable excipient or mixtures thereof, thereby attenuating expression of the target mRNA in the CNS of the subject.

### Claim 44

A method of providing neuroprotection to the CNS of a subject or treating a disease, a disorder or an injury of the CNS in a subject, comprising topically applying to the canal of the subject's ear an otic composition comprising at least one oligonucleotide which down regulates expression of a target gene associated with the disease disorder or injury, and a pharmaceutically acceptable excipient or mixtures thereof, thereby providing neuroprotection or treating the subject.

### Claim at position 24

45-62. (canceled)

### Claim 63 (depends on 28)

The composition according to claim 28, further comprising a permeability enhancer.

### Claim 64 (depends on 28)

The otic composition of claim 28, wherein the target gene is selected from one or more of SEQ ID NOS:1-293.

### Claim at position 27

65-78. (canceled)
